Home › Funds › Rangeley Capital, LLC › ABUS

Rangeley Capital, LLC position in ABUS

ARBUTUS BIOPHARMA CORP · Health Care

Rangeley Capital, LLC reported holding 500,000 shares of ABUS (ARBUTUS BIOPHARMA CORP) in its Q2 2026 13F filing — a position valued at US$2.4M, representing 2.29% of its reported portfolio and ranking #8 among its reported holdings. Rangeley Capital, LLC has disclosed ABUS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)500.00K sh
Reported value held$2.40M
Portfolio Weight2.29%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Rangeley Capital, LLC's ABUS position evolved

Rangeley Capital, LLC first disclosed a stake in ABUS in Q4 2024 at 1,459,000 shares (US$4.8M). Across 7 filings, Rangeley Capital, LLC increased the stake 0 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 500,000 shares valued at US$2.4M. Notable position changes include a 36% trim in Q2 2025 (shares rose 47% over the following quarter), a 40% trim in Q1 2026 (shares rose 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 1.46M $4.77M New
Q1 2025 1.35M $4.71M Reduce
Q2 2025 865.00K $2.67M Reduce
Q3 2025 840.00K $3.81M Reduce
Q4 2025 840.00K $4.04M Hold
Q1 2026 500.00K $2.25M Reduce
Q2 2026 500.00K $2.40M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABUS and 13F data

ABUS (ARBUTUS BIOPHARMA CORP) is a Health Care company. 43 other funds we track also report a position in ABUS — the largest reported positions include Whitefort Capital Management, LP (US$75.8M), Two Seas Capital LP (US$38.9M), BlackBarn Capital Partners LP (US$12.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABUS

All ABUS fund holders →

FAQ

How long has Rangeley Capital, LLC held ABUS?

Rangeley Capital, LLC has disclosed ABUS holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Rangeley Capital, LLC's current position in ABUS?

As of Q2 2026, Rangeley Capital, LLC holds 500.00K shares of ABUS (ARBUTUS BIOPHARMA CORP), valued at $2.40M, representing 2.29% of its reported portfolio and ranking #8.

Has Rangeley Capital, LLC been buying or selling ABUS?

In the latest 13F filing (Q2 2026), Rangeley Capital, LLC held unchanged its position in ABUS.

Which other funds hold ABUS?

Other major institutional holders of ABUS include Whitefort Capital Management, LP, Two Seas Capital LP, BlackBarn Capital Partners LP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.